Nanotechnology-based drug delivery of ropinirole for Parkinson’s disease

References

• Alam M, Schmidt WJ. (2002). Rotenone destroys dopaminergic neurons and induces Parkinsonian symptoms in rats. Behav Brain Res 136:317–24.
   PubMed Web of Science ®Google Scholar
• Bassani TB, Gradowski RW, Zaminelli T, et al. (2014). Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson’s disease model in rats. Brain Res 1593:95–105.
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, MacKenzie G, et al. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–6.
   PubMed Web of Science ®Google Scholar
• Bhatt D, Ajmeri N, Mandal S, et al. (2011). Nanoparticle: design, characterization and evaluation for oral delivery of ropinirole hydrochloride. Elixir Pharmacy 39:4687–9.
   Google Scholar
• Bisht R, Kaur B, Gupta H, et al. (2014). Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson’s disease in rats. Neurotoxicology 44:71–9.
   PubMed Web of Science ®Google Scholar
• Cannon JR, Tapias VM, Na HM, et al. (2009). A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis 34:279–90.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang X, Yang D, et al. (2008). D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett 582:603–710.
   PubMed Web of Science ®Google Scholar
• Choi WS, Kim HW, Xia Z. (2015). JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death. Toxicology 328:75–81.
   PubMed Web of Science ®Google Scholar
• Duty S, Jenner P. (2011). Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357–91.
   PubMed Web of Science ®Google Scholar
• Fernández M, Barcia E, Fernández-Carballido A, et al. (2012). Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson’s disease. Int J Pharm 438:266–78.
   PubMed Web of Science ®Google Scholar
• Fuster J, Negro S, Salama A, et al. (2015). HPLC-UV method development and validation for the quantification of ropinirole in new PLGA multiparticulate systems: microspheres and nanoparticles. Int J Pharm 491:310–17.
   PubMed Web of Science ®Google Scholar
• Gao Z, Zhu Q, Zhang Y, et al. (2013). Reciprocal modulation between microglia and astrocyte in reactive gliosis following the CNS injury. Mol Neurobiol 48:690–701.
   PubMed Web of Science ®Google Scholar
• García-García L, Delgado M, Al-Sayed AA, et al. (2015). In vivo [18F] FDG PET imaging reveals that p-chloroamphetamine neurotoxicity is associated with long-term cortical and hippocampal hypometabolism. Mol Imaging Biol 17:239–47.
   PubMed Web of Science ®Google Scholar
• Gomez C, Bandez MJ, Navarro A. (2007). Pesticides and impairment of mitochondrial function in relation with the Parkinsonian syndrome. Front Biosci 12:1079–93.
   PubMed Web of Science ®Google Scholar
• Haobam R, Sindhu KM, Chandra G, et al. (2005). Swim-test as a function of motor impairment in MPTP model of Parkinson’s disease: a comparative study in two mouse strains. Behav Brain Res 163:159–67.
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Couvreu P. (2009). Nanocarriers entry into the cell: relevance to drug delivery cell. Cell Mol Life Sci 66:2873–96.
   PubMed Web of Science ®Google Scholar
• Jost WH, Angersbach D. (2005). Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 11:253–72.
   PubMedGoogle Scholar
• Jost WH, Buhmann C, Fuchs G, et al. (2008). Initial experience with ropinirole PR (prolonged release). J Neurol 225(Suppl5):60–3.
   Web of Science ®Google Scholar
• Kasinathan N, Jagani HV, Alex AT, et al. (2015). Strategies for drug delivery to the central nervous system by systemic route. Drug Deliv 22:243–57.
   PubMed Web of Science ®Google Scholar
• Katiyar SS, Muntimadugu E, Rafeeqi TA, et al. (2016). Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment. Drug Deliv 23:2608–16.
   PubMed Web of Science ®Google Scholar
• Kudin AP, Bimpong-Buta NY, Vielhaber S, et al. (2004). Characterization of superoxide-producing sites in isolated brain mitochondria. J Biol Chem 279:4127–35.
   PubMed Web of Science ®Google Scholar
• Linazasoro G. (2008). Potential applications of nanotechnologies to Parkinson’s disease therapy. Parkinsonism Relat Disord 14:383–92.
   PubMed Web of Science ®Google Scholar
• Lockman PR, Koziara JM, Mumper RJ, et al. (2004). Nanoparticle surface charges altering blood-brain barrier integrity and permeability. J Drug Target 12:635–41.
   PubMed Web of Science ®Google Scholar
• Marcianes P, Negro S, García-García L, et al. (2017). Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis. Int J Nanomedicine 12:1959–68.
   PubMed Web of Science ®Google Scholar
• Messripour M, Mesripour A. (2013). Age related interaction of dopamine and serotonin synthesis in striatal synaptosomes. Biocell 37:17–21.
   PubMed Web of Science ®Google Scholar
• Park G, Park YJ, Yang HO, et al. (2013). Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism. Pharmacol Biochem Behav 104:163–8.
   PubMed Web of Science ®Google Scholar
• Pilati N, Barker M, Panteleimonitis S, et al. (2008). A rapid method combining Golgi and Nissl staining to study neuronal morphology and cytoarchitecture. J Histochem Cytochem 56:539–50.
   PubMed Web of Science ®Google Scholar
• Reis CP, Neufeld RJ, Ribeiro AJ, et al. (2006a). Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2:8–21.
   PubMed Web of Science ®Google Scholar
• Reis CP, Neufeld RJ, Ribeiro A, et al. (2006b). Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2:53–65.
   PubMed Web of Science ®Google Scholar
• Saravanan KS, Sindhu KM, Senthilkumar KS, et al. (2006). L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int 49:28–40.
   PubMed Web of Science ®Google Scholar
• Schapira AH. (1994). Mitochondrial function and neurotoxicity. Curr Opin Neurol 7:531.
   PubMed Web of Science ®Google Scholar
• Schapira AH. (2002). Dopamine agonists and neuroprotection in Parkinson’s disease. Eur J Neurol 9:7–14.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Cooper JM, Dexter D, et al. (1989). Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269.
   PubMed Web of Science ®Google Scholar
• Serlin Y, Shelef I, Knyazer B, et al. (2015). Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol 38:2–6.
   PubMed Web of Science ®Google Scholar
• Sherer TB, Betarbet R, Kim JH, et al. (2003). Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci Lett 341:87–90.
   PubMed Web of Science ®Google Scholar
• Sindhu KM, Saravanan KS, Mohanakumar KP. (2005). Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 1051:25–34.
   PubMed Web of Science ®Google Scholar
• Sofroniew MV, Vinters HV. (2010). Astrocytes: biology and pathology. Acta Neuropathol 119:7–35.
   PubMed Web of Science ®Google Scholar
• Spuch C, Saida O, Navarro C. (2012). Advances in the treatment of neurodegenerative disorders employing nanoparticles. Recent Pat Drug Deliv Formul 6:2–18.
   PubMedGoogle Scholar
• Stocchi F, Hersh BP, Scott BL, et al. (2008). Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 24:2883–95.
   PubMed Web of Science ®Google Scholar
• Swarnkar S, Goswami P, Kamat PK, et al. (2013). Rotenone-induced neurotoxicity in rat brain areas: a study on neuronal and neuronal supportive cells. Neuroscience 230:172–83.
   PubMed Web of Science ®Google Scholar
• Swarnkar S, Singh S, Goswami P, et al. (2012). Astrocyte activation: a key step in rotenone induced cytotoxicity and DNA damage. Neurochem Res 37:2178–89.
   PubMed Web of Science ®Google Scholar
• Tapias V, Greenamyre JT, Watkins SC. (2013). Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro. Neurobiol Dis 54:158–68.
   PubMed Web of Science ®Google Scholar
• Thomas DM, Walker PD, Benjamins JA, et al. (2004). Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311:1–7.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Wenning G, Poewe W. (2006). The diagnosis of Parkinson’s disease. Lancet Neurol 5:75–86.
   PubMed Web of Science ®Google Scholar
• Tompson DJ, Vearer D. (2007). Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease. Clin Ther 29:2654–66.
   PubMed Web of Science ®Google Scholar
• Uversky VN. (2004). Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318:225–41.
   PubMed Web of Science ®Google Scholar
• von Wrangel C, Schwabe K, John N, et al. (2015). The rotenone-induced rat model of Parkinson’s disease: behavioral and electrophysiological findings. Behav Brain Res 279:52–61.
   PubMed Web of Science ®Google Scholar
• Watabe M, Nakaki T. (2007). Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther 323:499–507.
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Gelperina S, Kreuter J. (2012). Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release 161:264–73.
   PubMed Web of Science ®Google Scholar
• Yun JY, Kim HJ, Lee JY, et al. (2013). Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson’s disease. BMC Neurol 13:113.
   PubMed Web of Science ®Google Scholar
• Zhang ZN, Zhang JS, Xiang J. (2017). Subcutaneous rotenone rat model of Parkinson’s disease: dose exploration study. Brain Res 15:104–13.
   Web of Science ®Google Scholar